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The peroxisome proliferator-activated receptor γ (PPARγ) agonist rosiglitazone (Rosi) ap-
pears to provide protection against organ dysfunction during endotoxaemia. We exam-
ined the potential benefits of Rosi on skeletal muscle protein maintenance and carbohy-
drate metabolism during lipopolysaccharide (LPS)-induced endotoxaemia. Sprague-Dawley
rats were fed either standard chow (control) or standard chow containing Rosi (8.5 +− 0.1
mg · kg−1 ·day−1) for 2 weeks before and during 24 h continuous intravenous infusion of LPS
(15 μg · kg−1 ·h−1) or saline. Rosi blunted LPS-induced increases in muscle tumour necro-
sis factor-α (TNF-α) and interleukin-6 (IL-6) mRNA by 70% (P<0.05) and 64% (P<0.01)
respectively. Furthermore, Rosi suppressed the LPS-induced reduction in phosphorylated
AKT and phosphorylated Forkhead box O (FOXO) 1 protein, as well as the up-regulation of
muscle RING finger 1 (MuRF1; P<0.01) mRNA and the LPS-induced increase in 20S pro-
teasome activity (P<0.05). Accordingly, LPS reduced the muscle protein:DNA ratio (∼30%,
P<0.001), which Rosi offset. Increased muscle pyruvate dehydrogenase kinase 4 (PDK4)
mRNA (P<0.001) and muscle lactate accumulation (P<0.001) during endotoxaemia were
suppressed by Rosi. Thus, pre-treatment with Rosi reduced muscle cytokine accumulation
and blunted muscle protein loss and lactate accumulation during endotoxaemia, and at
least in part by reducing activation of molecular events known to increase muscle protein
breakdown and mitochondrial pyruvate use.
Introduction
Skeletalmuscle wasting and the development ofmuscle lactic acidosis and insulin resistance are important
clinical consequences of sepsis, and if sustained, can have a detrimental impact on patient recovery and
survival. The rapid and marked loss of skeletal muscle mass during sepsis is thought to, in part, reflect the
activation of several pathways important in muscle protein breakdown, including ubiquitin–proteasome
pathway (UPP)-, calpain- and lysosome-dependent proteolytic pathways [1–4]. Sepsis also results in the
inhibition of muscle carbohydrate oxidation, not least by increasing muscle pyruvate dehydrogenase
kinase 4 (PDK4) abundance, which inhibits pyruvate dehydrogenase complex (PDC) activation [5–7],
thereby decreasing PDC flux and increasingmuscle lactate accumulation. Importantly, it has been demon-
strated that pro-inflammatory cytokines, and in particular tumour necrosis factor-α (TNF-α), play a ma-
jor role in the aetiology of muscle atrophy [8] and dysregulation of muscle carbohydrate metabolism [9].
Thus, suppressing the production of pro-inflammatory cytokines during sepsis may prove beneficial in
reducing the loss of muscle mass, maintaining carbohydrate oxidation and reducing lactic acidosis asso-
ciated with this condition.
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Increasing evidence suggests that activation (dephosphorylation) of the Forkhead box O (FOXO) family of tran-
scription factors, through suppression of AKT signalling, plays an important part in triggeringmuscle atrophy, partly
via the transcriptional up-regulation of muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MuRF1), which
are key mediators of UPP-dependent skeletal muscle proteolysis [10–12]. FOXO transcription factors may also play
an important role in the inhibition of muscle carbohydrate oxidation in catabolic conditions, through up-regulation
of PDK4 transcription and consequently decreased PDC activation and flux [13,14]. Indeed, we have provided sub-
stantive evidence supporting a role for cytokine-mediated suppression of the AKT/FOXO signalling pathway in the
simultaneous induction of muscle atrophy and impairment of muscle carbohydrate oxidation during lipopolysaccha-
ride (LPS)-induced endotoxaemia in rodents [15,16].
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of
ligand-activated transcription factors [17]. Chronic administration of the potent and selective PPARγ agonist rosigli-
tazone (Rosi; [18]) has been reported to improve insulin sensitivity and suppress UPP-dependent muscle protein
breakdown in a leptin receptor-deficient mouse model (db/db) of dyslipidaemia-mediated insulin resistance [19],
which was attributed to the preservation of AKT/FOXO signalling in db/db mice [19]. PPARγ agonists may also
be useful in the treatment of inflammatory conditions. For example, in animal models of endotoxaemia, treatment
with PPARγ activators has been shown to reduce circulating TNF-α and IL-1β in LPS-treated mice [20], and also
to have protective effects on multiple organs following LPS treatment by unresolved mechanisms [21–23]. How-
ever, the potential beneficial effects of PPARγ agonists on maintenance of skeletal muscle metabolic function during
endotoxaemia, and in particular, their impact on skeletal muscle atrophy and/or carbohydrate metabolism during
endotoxaemia, have not been reported.
In the present study, therefore, we hypothesized that administration of Rosi to rodents for 2 weeks before and dur-
ing endotoxaemia would reduce LPS-induced skeletal muscle cytokine mRNA abundance. As a direct consequence
of this, we anticipated cytokine-mediated up-regulation of several molecular events known to increase muscle pro-
tein breakdown and lactate accumulation and reduce carbohydrate oxidation would be supressed. Accordingly, we
proposed Rosi administration would blunt the induction of muscle protein loss and dysregulation of oxidative car-
bohydrate use that we have previously observed in skeletal muscle during endotoxaemia [15].
Experimental
Ethical approval
All procedures were approved by theUniversity of NottinghamEthicalReviewCommittee andwere performed under
Home Office Project and Personal Licence authority (Animal Scientific Procedures Act 1986).
Animals
Male Sprague-Dawley rats (350–450 g)were purchased fromCharlesRiver (Margate,U.K.) andhoused in theBiomed-
ical Services Unit at the University of Nottingham, with free access to food and water. Room temperatures weremain-
tained at 21 +− 2◦C, and lights were on from 06.00 to 18.00 h.
Experimental design, surgical preparation and tissue collection
Animals were divided into two groups: one group (n=16) was fed a standard rat chow (Teklad Global 18% protein
rodent diet, Bicester, Oxon, U.K.) supplemented with Rosi (0.1 mg · g−1 food; Bepharm Ltd., China) for 14 days (and
throughout subsequent experiments). A control (‘Con’) group (n=16) received standard rat chow. During the 14-day
period, the rats were housed in pairs, with daily food intakemeasured twice weekly. Based upon the daily food intake,
the average intake of Rosi was calculated to be 8.5 +− 0.1 mg · kg−1 · day−1. The dose of Rosi to be administered was
chosen on the basis of the work of Wang et al. [19], who demonstrated improvements in muscle AKT signalling in
a mouse model of insulin resistance when Rosi was administered chronically at a dose of 8 mg · kg−1 · day−1 for 35
days.
After 14 days, animals were anaesthetized (fentanyl citrate (Janssen-Cilag, High Wycombe, U.K.) and medetomi-
dine (Domitor; Pfizer, Sandwich, UK; 300 μg · kg−1 of each i.p.)) and intravenous catheters were implanted in the
right jugular vein. Anaesthetic reversal and the provision of analgesia were achieved with s.c. atipamezole (Anti-
sedan; Pfizer, Sandwich, U.K.; 1 mg · kg−1) and buprenorphine (Vetergesic; Alstoe Animal Health, York, U.K.; 0.03
mg · kg−1), and animals were returned to individual home cages. The catheters were connected to fluid-filled swivels
for overnight infusion of heparinized saline (15 U ·ml−1, 0.4 ml · h−1) to maintain catheter patency.
Experiments began 24 h after catheterization. Eight of the prepared animals in each of the two diet groups were
subjected to a continuous 24 h infusion of LPS (15μg · kg−1 · h−1; Escherichia coli serotype 0127:B8; Sigma–Aldrich,
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Poole, U.K.). The remaining animals in each diet group (n=8 per group) received an equal volume of saline (‘Sal’;
0.4 ml · h−1) for 24 h. After 24 h, animals were terminally anaesthetized with thiobutabarbital sodium (Inactin;
Sigma–Aldrich, St. Louis, U.S.A.; 80 mg · kg−1 i.v.), after which the extensor digitorum longus (EDL) muscle from
both hindlimbs was removed and immediately snap-frozen in liquid nitrogen. The EDL muscle was selected due to
its high susceptibility to atrophy during endotoxaemia [15,24].
Muscle protein and DNA measurements
Themuscle protein:DNA ratio was used to assess changes inmuscle proteinmass, as it has previously been shown that
reduced skeletal muscle protein content is a consistent feature of critically ill patients [25,26], in the face of substantial
increased extracellular muscle water content. These findings strongly suggest that under catabolic conditions where
substantial changes in tissue fluid may occur, the protein:DNA ratio may be a more reliable measure of changes in
muscle protein mass than other approaches such as cross-sectional area or muscle weight.
A portion of frozen EDL muscle was freeze-dried and powdered, and alkaline-soluble protein and DNA were
extracted from 2 to 3mg powderedmuscle according to Forsberg et al. [27]. Briefly, powderedmuscle was extracted in
0.2 mol · l−1 perchloric acid (PCA), before being centrifuged at 3000 g for 15 min. The muscle residue was dissolved
in 0.3 mol · l−1 KOH and samples were assessed for alkaline-soluble protein, using the Lowry method [28]. In the
same extract, DNA was hydrolyzed by incubating in 1 mol · l−1 PCA at 70◦C and the digest was used to measure
DNA using a modification of the diphenylamine method [27].
Real-time PCR measurements
Total RNA was isolated from frozen wet EDL muscle (20–30 mg) using Tri Reagent (Sigma–Aldrich, Poole, U.K.),
according to the manufacturer’s protocol. RNA was quantified through spectrophotometric measurement at 260 and
280 nm, and reverse transcription was carried out in a reaction comprising of 1 μg RNA, random primers, MMLV re-
verse transcriptase, dNTPs and RNase inhibitor (all from Promega, Southampton, U.K.). Resulting cDNAwas diluted
4-fold andused in real-timePCR reactions in anABIPrism 7700 SequenceDetection system (AppliedBiosystems) us-
ing Assay-on-DemandTaqman R© primer/probe sets (PPARγ, TNF-α, interleukin-6 (IL-6), FOXO1, MAFbx, MuRF1,
PDK4 and cathepsin-L) fromApplied Biosystems (Foster City, U.S.A.). The housekeeping gene hydroxymethylbilane
synthase (HMBS) was used as an internal control as it was unaffected by the treatments (data not shown).
Relative changes in mRNA expression between groups were calculated using the 2−C t method, normalized
against HMBS. A calibrator in the Con/Sal group was given a value of 1, and fold changes in mRNA expression
for the Con/LPS-treated, Rosi/Sal-treated and Rosi/LPS-treated groups were calculated, relative to the calibrator.
Protein extraction and Western blotting measurements
Proteins were extracted from 20 to 30 mg frozen wet tissue by homogenization in a buffer consisting of 50 mM
Tris/HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate, 50 mM NaF and complete protease in-
hibitor tablet (Roche, West Sussex, U.K.). Extracts were centrifuged at 13000 g for 10 min at 4◦C to collect the super-
natant. Protein samples (10 μg) were run on Criterion XT 4–12% Bis-Tris gels (Bio-Rad, Hemel Hempstead, U.K.)
at 200 V for 1 h, and transferred to PVDF membranes for 1 h at 100 V. Membranes were blocked in 2.5% BSA di-
luted in Tris-buffered saline (TBS) and 0.1% Tween-20 and incubated with primary antibodies (phosphorylated AKT
(Ser473; pAKT, #4058), phosphorylated FOXO1 (Ser256; pFOXO1, #9461) phosphorylated FOXO3 (Ser253; pFOXO3,
#9466), total AKT (#4691), total FOXO1 (#2880) and total FOXO3 (#12829); all from Cell Signaling Technology,
Danvers, U.S.A.) diluted 1:2000 overnight at 4◦C. Membranes were washed 3 × 5 min with TBS-Tween, incubated
with peroxidase-conjugated anti-rabbit secondary antibody (New England Biolabs, Hitchin, U.K.) 1:2000 for 1 h at
room temperature, and incubated with enhanced chemiluminescence detection reagent (Millipore, Watford, U.K.).
Bands were visualized using a Chemidoc XRS system (Bio-Rad, Hemel Hempstead, U.K.), and were quantified by
measurement of peak density and normalization against Coomassie Brilliant Blue staining of the membrane.
Muscle metabolite measurements
Freeze-dried and powderedmuscle samples (5–10mg)were extracted using 0.5mol · l−1 PCAcontaining 1mmol · l−1
EDTA, then neutralizedwith 2.1mol · l−1 KHCO3.Muscle lactate concentrationwas determined using amodification
of the spectrophotometric method of Harris et al. [29].
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Figure 1. Effect of Rosi on alkaline-soluble protein (A), DNA (B) and the protein to DNA ratio (C) in EDL muscle following
24-h LPS or saline (Sal) infusion
Values represent mean + SEM and n=8 for each group. Significantly different from Con/Sal: ***P<0.001.
Muscle enzyme activity measurements
Frozen muscle (15–25 mg) was homogenized, and the soluble muscle extract was used to
measure the chymotrypsin-like activity of the 20S proteasome using the fluorogenic substrate
N-Suc-Leu-Leu-Val-Tyr-7-Amido-4-Methyl-Coumarin (Sigma–Aldrich, Poole, U.K.), according to Dawson et
al. [30]. The same muscle homogenate was also used to determine cathepsin-L activity using the substrate
Z-Phe-Arg-7-Amido-4-Methyl-Coumarin (Sigma–Aldrich, Poole, U.K.), according to Bergmeyer [31].
Statistical analysis
Data are presented asmean+− SEM.Comparisons between treatment groupswere performed using one-wayANOVA,
with the Fisher’s least significant difference (LSD) post hoc test being used to locate any significant differences.
P<0.05 was taken as statistically significant.
Results
The average body mass of rats fed the diet supplemented with Rosi increased by 100 +− 8 g during the 14-day period,
which was no different to the increase of 107 +− 7 g observed in animals fed the Con diet. Average food intake during
this period was no different between treatment groups, and was calculated to be 85.0 +− 1.4 g · kg−1 · day−1 in animals
fed the Con diet compared with 78.0 +− 1.0 g · kg−1 · day−1 in rats fed the Rosi supplemented diet.
Treatment with Rosi for 14 days had no effect on any of the measured variables in saline-infused animals (with the
exception ofmuscle PPARγmRNA expression; see below). Thus, there were no significant differences between any of
the measurements made, i.e. in terms of muscle protein catabolism, cytokine abundance and AKT/FOXO signalling
pathways, when comparing animals that received the Con diet plus saline-infusion (Con/Sal) versus Con diet with
Rosi plus saline-infusion (Rosi/Sal; Figures 1–5).
Protein:DNA ratio
Compared with Con/Sal, muscle alkaline-soluble protein and the protein:DNA ratio were ∼30% lower in Con plus
LPS-treated (Con/LPS) animals (both P<0.001; Figure 1A and C), indicating that LPS infusion exerted a significant
catabolic effect on EDL muscle. DNA content was no different across treatment groups (Figure 1B). In Rosi-treated
rats infused with LPS (Rosi/LPS), the protein:DNA ratio was not different from that in Rosi/Sal-treated animals;
however, there was also no significant difference between the protein:DNA ratio in Con/LPS and Rosi/LPS-treated
animals (but there was a trend for the alkaline-soluble protein content to be lower in Con/LPS, P=0.1; Figure 1A).
These findings indicate that Rosi administration was able to suppress the loss of muscle protein associated with en-
dotoxaemia.
Muscle mRNA expression
Differences in muscle mRNA expression in Con/LPS-, Rosi/Sal- and Rosi/LPS-treated animals relative to
Con/Sal-treated animals are shown in Figure 2. PPARγ mRNA expression was greater in Con/LPS-, Rosi/Sal-
and Rosi/LPS-treated animals compared with Con/Sal-treated animals. LPS infusion in rats fed the control diet
resulted in markedly greater mRNA expression of TNF-α (13-fold, P<0.01), IL-6 (14-fold, P<0.001), FOXO1
(3.9-fold, P<0.001), MAFbx (4.8-fold, P<0.01), MuRF1 (17-fold, P<0.001), cathepsin-L (16-fold, P<0.001) and
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Figure 5. Effect of Rosi on 20S proteasome (A) and cathepsin-L (B) activity in rat EDL muscle following 24 h of LPS or saline
(Sal) infusion
Values are mean and vertical bars represent SEM and n=8 for each group. Significantly different from Con/Sal group: *P<0.05; **P<0.01.
Significantly different from Con/LPS group: #P<0.05.
Figure 2. Effect of Rosi on the mRNA expression of (A) PPARγ, (B) TNF-α, (C) IL-6, (D) FOXO1, (E) MAFbx, (F) MuRF1, (G)
cathepsin-L and (H) PDK4 in rat EDL muscle following 24-h LPS or saline (Sal) infusion
Relative mRNA expression of saline controls was set at 1. Values are mean and vertical bars represent SEM and n=8 for each group.
Significantly different from Con/Sal: *P<0.05; ** P<0.01; ***P<0.001. Significantly different from Con/LPS group: #P<0.05; ##P<0.01.
PDK4 (15-fold, P<0.001) relative to Con/Sal-treated animals. These findings are consistent with previous observa-
tions during endotoxaemia in EDL muscle [15,16]. Rosi treatment markedly supressed the LPS-induced increases in
mRNA expression for all genes analysed, with the exception of MAFbx, where the difference did not reach statistical
significance (P=0.07 versus Con/LPS; Figure 2E). Thus, Rosi administration significantly suppressed LPS-induced
increases in mRNA expression of genes linked to inflammatory signalling and catabolic processes.
Muscle protein expression
Infusion of LPSwas associatedwith significantly less (∼25%)muscle phosphorylatedAKT (Ser473) expression relative
to Con/Sal-treated animals (P<0.05; Figure 3A), consistent with a suppression of AKT signalling, whereas there was
no significant difference in phosphorylated AKT expression between Rosi/LPS-treated animals and Rosi/Sal-treated
animals. Expression of totalAKTwas unaffected by treatments (Figure 3B). Similarly, phosphorylatedFOXO1 (Ser256)
and FOXO3 (Ser253) protein expression was less in Con/LPS relative to Con/Sal-treated animals (∼45%, P<0.001,
Figure 3C; ∼45%, P<0.001, Figure 3E respectively). There was no difference in FOXO1 (Ser256) expression levels
between Rosi/Sal- and Rosi/LPS-treated animals (Figure 3C), but in the case for FOXO3 (Ser253) protein expression
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Figure 3. Effect of Rosi on phosphorylation of AKTSer473 (A), total AKT (B), FOXO1Ser256 (C), total FOXO1 (D), FOXO3Ser253
(E) and total FOXO3 (F) in rat EDL muscle following 24-h LPS or saline (Sal) infusion
Values represent mean + SEM and n=8 for each group. Representative blots for each protein measured are shown for 2 of 8 animals in
each experimental group. Significantly different from Con/Sal or Rosi/Sal: *P<0.05; ***P<0.001.
was less in Rosi/LPS relative to Rosi/Sal-treated animals (∼20%, P<0.05, Figure 3E). Thus, Rosi appeared to prevent
the LPS-induced reduction in FOXO1 but not FOXO3 phosphorylation. There was also no difference in AKT (Ser473)
expression and phosphorylated FOXO1 (Ser256) expressionwhen comparingCon/LPS- andRosi/LPS-treated animals
(Figure 3A and C). Finally, there were no differences in total FOXO1 (Figure 3D) or total FOXO3 (Figure 3F) across
treatment groups.
Muscle lactate and enzyme activities
Muscle lactate concentrationwas 2-fold greater inCon/LPS comparedwithCon/Sal-treated animals (P<0.001;Figure
4), whereas it was not significantly greater in Rosi/LPS versus Rosi/Sal-treated animals. There was also a trend for
muscle lactate concentration to be lower in Rosi/LPS compared with Con/LPS-treated animals (P=0.08; Figure 4).
Muscle 20S proteasome activity was 1.5-fold greater in Con/LPS-treated animals compared with Con/Sal-treated
animals, while 20S proteasome activity was no different between Rosi/Sal- and Rosi/LPS-treated animals (P<0.01;
Figure 5A), indicating that the LPS-associated increases in UPP-dependent muscle protein breakdown were sup-
pressed by Rosi. Furthermore, 20S proteasome activity was significantly less in Rosi/LPS versus Con/LPS-treated
animals (P<0.05; Figure 5A). Muscle cathepsin-L activity was significantly greater in Con/LPS-treated rats com-
pared with Con/Sal (1.3-fold, P<0.05; Figure 5B), whereas cathepsin-L activity was no different between Rosi/LPS-
and Rosi/Con-treated animals. However, cathepsin-L activity in Con/LPS-treated rats was not different from
Rosi/LPS-treated animals (Figure 5B).
Discussion
To our knowledge, this is the first study to demonstrate clear protective effects of PPARγ agonism on muscle pro-
tein loss and lactate accumulation during in vivo LPS-induced endotoxaemia. It also provides mechanistic insight
of the molecular events underpinning this protection. We hypothesized that dietary administration of the PPARγ
agonist Rosi to rodents for 2 weeks before and during 24 h of LPS-induced endotoxaemia would reduce skeletal
muscle cytokine mRNA abundance that we have previously observed in skeletal muscle during endotoxaemia [15].
We hypothesized further that as a direct consequence of this, cytokine provoked up-regulation of several molec-
ular events known to increase muscle protein breakdown and lactate accumulation, and reduce carbohydrate oxi-
dation, would be suppressed. More specifically, we speculated that Rosi administration would blunt LPS-mediated
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Figure 4. Lactate concentrations in rat EDL muscle
Lactate content in EDL muscle from rats administered with LPS or saline (Sal) for 24 h, following Rosi treatment. Values are mean and
vertical bars represent SEM and n=8 for each group. Significantly different from Con/Sal group: ***P<0.001.
down-regulation of muscle AKT signalling, activation of FOXO transcription factors and up-regulation of down-
stream FOXO targets thought to mediate proteolysis (MAFbx, MuRF1 and cathepsin-L) and limit mitochondrial
pyruvate oxidation (PDK4). In keeping with this, our results convincingly demonstrate that Rosi treatment exerted
a significant anti-inflammatory effect in muscle during endotoxaemia (Figure 2B and C), which was associated with
preservation of phosphorylation of AKT (activation, Figure 3A) and FOXO1 (inactivation, Figure 3B) and markedly
reduced mRNA expression of key factors involved in muscle protein breakdown (i.e. FOXO1, MuRF1, cathepsin-L;
Figure 2D, F and G respectively). This coincided with the suppression of 20S proteasome activity in Rosi/LPS-treated
animals (Figure 5A). Moreover, treatment with Rosi appeared to offset the LPS-induced reduction in the muscle pro-
tein:DNA ratio (Figure 1C). The findings that PDK4 mRNA expression (Figure 2H) and muscle lactate concentration
(Figure 4) were lower in Rosi/LPS-treated rats strongly suggest that Rosi also had a beneficial effect onmitochondrial
pyruvate utilization. Collectively, these results are consistent with the involvement of cytokine-mediated modulation
of muscle AKT/FOXO1-dependent signalling during endotoxaemia, which can be supressed by PPARγ agonism,
thereby reducing muscle atrophy and maintaining mitochondrial pyruvate use.
Previous rodent studies have reported protective effects of PPARγ agonism in organ damage caused by endotox-
aemia [21–23], which were exerted by both receptor-mediated actions and anti-inflammatory properties of PPARγ
agonists [32]. The markedly lower expression of muscle TNF-α and IL-6 mRNA in Rosi/LPS-treated animals (Figure
2B and C), along with the preservation of the muscle protein:DNA ratio in these same animals (Figure 1C; which is
a reliable marker for changes in muscle protein mass, particularly during sepsis where significant changes in tissue
fluid content occur [25]), suggests that the protective effects of PPARγ agonism was due to an anti-inflammatory in-
fluence. Furthermore, the finding that Rosi/Sal and Rosi/LPS treatments elicited similar increases in muscle PPARγ
mRNA expression (Figure 2A) supports this suggestion, and also indicates the protective effects exerted by Rosi may
not have been PPARγ-dependent per se. Inclusion of a PPARγ antagonist to test whether the effects observed by
Rosi were directly dependent on PPARγ activation would help to confirm these results. We have previously shown
that suppressing the increase in muscle pro-inflammatory cytokine mRNA expression during 24-h LPS infusion by
concurrently infusing low-dose dexamethasone (Dex), a potent synthetic glucocorticoid, also preserved the mus-
cle protein:DNA ratio [16], lending further support to our assertion. Given LPS has been shown to down-regulate
PPARγmRNA and protein expression in vivo in hepatic tissue and in vitro in Kupffer cells and HepG2 cells via both
TNF-α- [33] and IL6-mediated [34] mechanisms, the elevation in PPARγ mRNA expression in the skeletal muscle
of Con/LPS-treated animals above Con/Sal-treated animals in the present study was unexpected and is not easily
explained.
Down-regulation of AKT signalling in inflammatory catabolic conditions is associated with dephosphorylation
(activation) of FOXO transcription factors and increased mRNA expression of FOXO downstream gene targets
[12,19], which we have confirmed in skeletal muscle in the same rat model of LPS-induced endotoxaemia as used
in the present study [15]. Furthermore, we have demonstrated in this same rodent model of clinical endotoxaemia
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that suppression of LPS-induced muscle cytokine elevation achieved by concurrent low dose Dex infusion preserves
phosphorylation ofAKT (activation) andFOXO1 (inhibition), reduces abundance and activation of theirdownstream
targets andmaintainsmuscle protein content [16]. Since PPARγ agonists are known to be anti-inflammatory [32] and
chronic administration of Rosi has been demonstrated to prevent the down-regulation of AKT signalling, activation
of FOXO1 and muscle protein breakdown in a genetic mouse model (db/db) of dyslipidaemia-mediated insulin re-
sistance [19], we aimed to determine whether Rosi administration would result in similar positive events during the
acute catabolic state of LPS-induced endotoxaemia and thereby attenuate the muscle protein loss that occurs. Con-
sistent with the observations of Wang et al. [19], administration of Rosi for 14 days prior to and during LPS-induced
endotoxaemia appeared to, at least partially, prevent the LPS-induced reduction in phosphorylated or ‘active’ AKT
protein, since therewas no significantdifference in phosphorylatedAKT inmuscles of Rosi/LPS-treated animals com-
pared with the Rosi/Sal group (Figure 3A). Also in line with the findings of Wang et al. [19], the LPS-induced increase
in FOXO1 mRNA expression was significantly reduced by Rosi treatment (Figure 2D), and the LPS-mediated reduc-
tion in cytosolic FOXO1 (protein) dephosphorylationwas prevented by Rosi administration (Figure 3C).Collectively,
these events were associatedwith the preservation ofmuscle protein content (Figure 1), but Rosi didnot appear to pre-
vent the LPS-induced reduction in FOXO3 phosphorylation (Figure 3E). It is not completely clear why Rosi inhibited
LPS-induced reductions in FOXO1, but not FOXO3 phosphorylation. It is feasible that their phosphorylation sites
may be regulated by different upstream proteins, or that FOXO1 was more responsive to the Rosi-mediated reduc-
tion in cytokine expression levels than FOXO3. Given phosphorylation (inactivation) of FOXO transcription factors
occurs on three conserved residues, and in the present study we determined FOXO1 Ser256 and FOXO3 Ser253, we
can speculate that Rosi may have attenuated LPS-induced dephosphorylation on the Ser256 site, but not on the Ser253
site, thereby explaining our observation.
Since increased activity of the UPP is thought to significantly contribute to muscle protein loss during sepsis
[1,35,36], the greater mRNA expression of MAFbx and MuRF1 and activity of the 20S proteasome observed with
Con/LPS treatment in the present study (Figures 2E, 2F and 5A), as seen previously with this model [15,16], clearly
point to increased UPP activity being, at least partly, responsible for the reduced muscle protein:DNA ratio observed
in these animals. More importantly, however, Rosi treatment significantly dampened the LPS-induced increases in
muscle MuRF1 mRNA (Figure 2F), tended to reduce the increase in MAFbx mRNA (Figure 2E) and significantly
diminished muscle 20S proteasome activity (Figure 5A). Collectively, these findings convincingly indicate that Rosi
was able to suppress muscle UPP-dependent protein breakdown during endotoxaemia, and at least in part by di-
minishing the cytokine-mediated burden on AKT and FOXO1 signalling. It should be acknowledged however that
nuclear factor kappa B (NF-κB) and p39 mitogen-activated protein kinase (MAPK) signalling pathways have also
been implicated in the cytokine-dependent up-regulation of the proteasome system [37,38].
Evidence also exists supporting a role for FOXO family transcription factors in the up-regulation of muscle au-
tophagy and lysosomal proteolysis [39–41]. Indeed, cathepsin-L, a lysosomal protease that is up-regulated in a variety
ofmodels ofmuscle atrophy [42,43], andmost likely by a cytokinemediatedmechanism [44], is a FOXO1 downstream
gene target in skeletal muscle [45]. We have previously shown cathepsin-L to be up-regulated at both the mRNA and
protein level in endotoxaemia [16], which was dampened by Dex-mediated suppression of LPS-induced muscle cy-
tokine elevation [16]. In the present study, Con/LPS treatment markedly increased cathepsin-L mRNA expression,
which was robustly blunted in Rosi/LPS-treated animals, presumably also due to the anti-inflammatory properties
of Rosi (Figure 2G). Furthermore, whilst muscle cathepsin-L activity was greater in Con/LPS-treated animals com-
pared with Con/Sal-treated animals, activity was no different between Rosi/LPS-treated and Rosi/Sal-treated animals
(it is acknowledged that cathepsin-L activity was also no different between Con/LPS- and Rosi/LPS-treated animals;
Figure 5B). Therefore, based upon cathepsin-LmRNA expression and protein activitymeasurements, it would appear
that Rosi had some capacity to blunt an LPS-induced increase in cathepsin-L-mediated muscle protein breakdown,
thereby contributing to the preservation of muscle protein content observed, and presumably also by dampening of
cytokine-mediated dysregulation of AKT/FOXO1 signalling in endotoxaemia.
Increased muscle PDK4 expression can lead to a down-regulation of muscle mitochondrial pyruvate oxidation,
through its ability to phosphorylate and thereby inactivate the mitochondrial PDC [46]. We have previously demon-
strated a cytokine-linked increase in PDK4 mRNA and protein expression, coupled to the inhibition of PDC ac-
tivity and stimulation of lactate accumulation in muscle during LPS-induced endotoxaemia in this rodent model
[7,15]. Furthermore, we have strongly implicated the dysregulation of AKT/FOXO signalling in these events [15].
The up-regulation of muscle PDK4 mRNA observed with Con/LPS treatment in the present study (Figure 2H), along
with the increase in muscle lactate accumulation (Figure 4), is entirely consistent with our previous observations
[7,15]. Moreover, we have also reported that blunting the cytokine response to LPS using low-dose Dex offset the dys-
regulation of Akt signalling, and normalized muscle PDK4 mRNA and protein expression, PDC activity and lactate
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accumulation [16]. Directly in keeping with this, the Rosi-mediated normalization of the muscle cytokine response
observed during Con/LPS treatment of the present study (Figure 2B and C) was associated with the suppression of
LPS-induced up-regulation of PDK4 mRNA expression (by 50%, Figure 2H), and the normalization of muscle lac-
tate accumulation (Figure 4) clearly suggesting Rosi administration maintained mitochondrial pyruvate utilization
during under these conditions.
In summary, this is the first study to demonstrate clear positive effects of PPARγ agonism on muscle protein
loss and lactate accumulation during in vivo LPS-induced endotoxaemia. Dietary administration of the PPARγ
agonist, Rosi, to rodents reduced skeletal muscle cytokine mRNA expression during in vivo LPS-induced endo-
toxaemia and dampened the LPS-mediated down-regulation of muscle AKT signalling, activation of FOXO1 tran-
scription factor, and up-regulation of FOXO downstream target genes thought to mediate proteolysis (MAFbx,
MuRF1 and cathepsin-L) and limit mitochondrial pyruvate oxidation (PDK4). This coincided with the suppres-
sion of 20S proteasome, and to a lesser extent cathepsin-L, activity in Rosi/LPS-treated animals. The findings that
PDK4 mRNA expression and muscle lactate concentration were lower in Rosi/LPS-treated rats strongly suggest that
Rosi had a beneficial effect on mitochondrial pyruvate utilization. Collectively, these results, along with our pre-
vious demonstration that low-dose Dex elicits similar events during LPS-induced endotoxaemia [16], are entirely
consistent with cytokine-mediated modulation of AKT/FOXO1-dependent signalling in muscle during endotox-
aemia, which if supressed (by either PPARγ agonism or glucocorticoid administration) can offset muscle net protein
loss (atrophy) and maintain mitochondrial pyruvate oxidation during endotoxaemia, and most likely by a common
AKT/FOXO1-dependent mechanism. The findings of the present study, therefore, contribute further insight towards
a better understanding of the mechanisms regulating muscle atrophy and carbohydrate oxidation during endotox-
aemia.
Clinical Perspectives
• Skeletal muscle wasting and muscle lactic acidosis are two important clinical consequences
of sepsis, that if prolonged, can have a detrimental impact on patient recovery and survival. We
aimed to determine the potential beneficial effects of PPARγ agonists on skeletal muscle atrophy
and/or carbohydrate metabolism during endotoxaemia in rats.
• Pre-treatment with the PPARγ agonist Rosi reduced muscle cytokine mRNA and alleviated mus-
cle protein loss and lactate accumulation during endotoxaemia, at least in part by reducing ac-
tivation of molecular events linked to increased muscle protein breakdown and mitochondrial
pyruvate use.
• We have demonstrated clear positive effects of Rosi on muscle wasting and lactate accumulation
during endotoxaemia in vivo, contributing further insight into our understanding of the mecha-
nisms underlying the regulation of muscle atrophy and mitochondrial pyruvate use during endo-
toxaemia.
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